专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5654174A Herpes simplex virus glycoprotein D variants 失效
标题翻译：单纯疱疹病毒糖蛋白D变体
公开(公告)号：US5654174A
公开(公告)日：1997-08-05
申请号：US499568
申请日：1995-07-07
申请人： Gary H. Cohen , Roselyn J. Eisenberg , Anthony Nicola
发明人： Gary H. Cohen , Roselyn J. Eisenberg , Anthony Nicola
IPC分类号： A61K38/00 , A61K39/00 , C07K14/035 , C12N15/38 , C12P21/02 , C12N5/10
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N2710/14143 , C12N2710/16622 , Y10S930/224
摘要： The present invention provides variant HSV-1 glycoprotein D and HSV-2 glycoprotein D molecules capable of preventing infection of cells by herpes simplex virus types 1 and/or 2. Also provided are novel purified and isolated polynucleotides encoding the variant gD molecules. HSV gD-1 and gD-2 region IV variants or fragments thereof are specifically contemplated by the invention. The presently preferred variant molecule gD-1(.DELTA.290-299t) is the product of recombinant expression in Sf9 cells of a fusion protein including the signal peptide of honeybee melittin and Patton strain HSV-1 gD wherein (1) the Patton strain amino acid residues 290 through 299 of the mature gD-1 protein have been replaced with the amino acid residues arginine, lysine, isoleucine and phenylalanine, and (2) Patton strain amino acid residues 308 through 369 have been replaced with five histidine residues. When expressed in Sf9 cells, cleavage of the melittin signal peptide results in the presence of aspartate and proline residues at the amino terminus of the variant molecule. The amino acid sequence of gD-1(.DELTA.290-299t) is set out in SEQ ID NO: 2 and the preferred DNA sequence encoding gD-1(.DELTA.290-299t) is set out in SEQ ID NO: 1. Administration of gD variant molecules of the invention to mammalian subjects, especially humans, for the purpose of preventing HSV infection and/or ameliorating pathological sequelae of HSV infection is specifically contemplated.
摘要翻译：本发明提供能够预防1型和/或2型单纯疱疹病毒感染细胞的变体HSV-1糖蛋白D和HSV-2糖蛋白D分子。还提供了编码变体gD分子的新型纯化和分离的多核苷酸。 HSV gD-1和gD-2区IV变体或其片段是本发明具体考虑的。目前优选的变体分子gD-1（DELTA 290-299t）是在融合蛋白的Sf9细胞中重组表达的产物，包括蜜蜂蜂毒素和巴顿菌株HSV-1 gD的信号肽，其中（1）Patton菌株氨基酸成熟gD-1蛋白的残基290至299已被氨基酸残基精氨酸，赖氨酸，异亮氨酸和苯丙氨酸替代，（2）Patton菌株氨基酸残基308至369被五个组氨酸残基取代。当在Sf9细胞中表达时，蜂毒肽信号肽的切割导致在变体分子的氨基末端存在天冬氨酸和脯氨酸残基。 gD-1（DELTA 290-299t）的氨基酸序列示于SEQ ID NO：2中，编码gD-1（DELTA 290-299t）的优选DNA序列列于SEQ ID NO：1中。具体考虑本发明的gD变体分子对于哺乳动物受试者，特别是人来说是为了预防HSV感染和/或改善HSV感染的病理后遗症的目的。

2. 发明授权

US5420026A Self-assembling replication defective hybrid virus particles 失效
标题翻译：自组装复制缺陷型杂交病毒颗粒
公开(公告)号：US5420026A
公开(公告)日：1995-05-30
申请号：US17124
申请日：1993-02-12
申请人： Lendon Payne
发明人： Lendon Payne
IPC分类号： A61K39/00 , A61K47/48 , A61K48/00 , C07K14/03 , C07K14/155 , C12N7/00 , C12N7/04 , C12N15/00 , C12N15/09 , C12N15/863 , C12P21/00 , C12P21/04 , C12R1/92 , C12N5/10 , C12N15/38 , C12N15/49 , C12N15/86
CPC分类号： C12N15/86 , C07K14/005 , C12N7/00 , A61K39/00 , C12N2710/16722 , C12N2710/16723 , C12N2710/24143 , C12N2740/15022 , C12N2740/15023 , Y10S930/221 , Y10S930/224
摘要： The invention pertains to self-assembled replication defective hybrid virus-like particles having capsid and membrane glycoproteins from at least two different virus types and method of making same. Recombinant viral vectors as well as the viral particles can be used as immunogens and drug delivery vehicles.
摘要翻译：本发明涉及具有来自至少两种不同病毒类型的衣壳和膜糖蛋白的自组装复制缺陷型杂合病毒样颗粒及其制备方法。重组病毒载体以及病毒颗粒可用作免疫原和药物递送载体。

3. 发明授权

US5245010A Polypeptide of herpes simplex virus Vmw 65 protein 失效
标题翻译：多肽的复制病毒VMW 65蛋白
公开(公告)号：US5245010A
公开(公告)日：1993-09-14
申请号：US820658
申请日：1992-01-17
申请人： Richard F. Greaves , Peter F. J. O'Hare
发明人： Richard F. Greaves , Peter F. J. O'Hare
IPC分类号： A61K38/55 , A61K39/395 , A61P31/12 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/035 , C07K16/00 , C12N7/00 , C12N15/09 , C12P21/08 , C12R1/91
CPC分类号： C07K14/005 , C12N2710/16622 , Y10S530/826 , Y10S930/224
摘要： A polypeptide which inhibits the replication of Herpes Simplex Virus and like viruses, which has the amino acid sequence of consecutive amino acids of HSV protein Vmw 65 and comprises the sequence 367 to 373: ##STR1## (identified as SEQ ID NO: 1) or a conservatively modified variant thereof, its therapeutic use and antibodies thereto.

4. 发明授权

US4824667A Thymidine kinase deletion mutants of bovine herpesvirus-1, vaccines against infectious bovine rhinotracheitis containing same and methods for the production and use of same 失效
标题翻译：牛疱疹病毒-1的胸苷激酶缺失突变体，含有其的感染性牛鼻气管炎疫苗，以及生产和使用它们的方法
公开(公告)号：US4824667A
公开(公告)日：1989-04-25
申请号：US78601
申请日：1987-07-28
申请人： Malon Kit , Saul Kit
发明人： Malon Kit , Saul Kit
IPC分类号： C12N15/09 , A61K39/245 , A61K39/265 , C12N7/00 , C12N7/04 , C12N15/00 , C12Q1/70 , C12R1/91 , A61K39/12
CPC分类号： C12N15/00 , A61K39/12 , A61K39/245 , C12N2710/16734 , Y10S424/813 , Y10S424/822 , Y10S930/224
摘要： Bovine herpesvirus type 1 (infectious bovine rhinotracheitis virus) mutants which fail to produce any functional thymidine kinase as a result of a deletion in the thymidine kinase gene. The deletion in the thymidine kinase gene attenuates the viruses so that they can be used as an active agent in a modified live-virus vaccine against infectious bovine rhinotracheitis. This invention also relates to methods for the production and use of the same.
摘要翻译：牛疱疹病毒1型（感染性牛鼻气管炎病毒）突变体，其由于胸苷激酶基因缺失而不能产生任何功能性胸苷激酶。在胸苷激酶基因中的缺失使病毒减毒，从而可以将其用作针对感染性牛鼻气管炎的改良活病毒疫苗中的活性剂。本发明还涉及其制备和使用方法。

5. 发明授权

US5858726A Self-assembling replication defective hybrid virus particles 失效
公开(公告)号：US5858726A
公开(公告)日：1999-01-12
申请号：US442471
申请日：1995-05-16
申请人： Lendon Payne
发明人： Lendon Payne
IPC分类号： A61K39/00 , A61K47/48 , A61K48/00 , C07K14/03 , C07K14/155 , C12N7/00 , C12N7/04 , C12N15/00 , C12N15/09 , C12N15/863 , C12P21/00 , C12P21/04 , C12R1/92 , A61K39/12
CPC分类号： C12N15/86 , C07K14/005 , C12N7/00 , A61K39/00 , C12N2710/16722 , C12N2710/16723 , C12N2710/24143 , C12N2740/15022 , C12N2740/15023 , Y10S930/221 , Y10S930/224
摘要： The invention pertains to self-assembled replication defective hybrid virus-like particles having capsid and membrane glycoproteins from at least two different virus types and method of making same. Recombinant viral vectors as well as the viral particles can be used as immunogens and drug delivery vehicles.

6. 发明授权

US5814486A Herpes simplex virus glycoprotein D variants 失效
标题翻译：单纯疱疹病毒糖蛋白D变体
公开(公告)号：US5814486A
公开(公告)日：1998-09-29
申请号：US793958
申请日：1997-05-07
申请人： Gary H. Cohen , Roselyn T. Eisenberg , Anthony Nicola
发明人： Gary H. Cohen , Roselyn T. Eisenberg , Anthony Nicola
IPC分类号： A61K38/00 , A61K39/00 , C07K14/035 , C12N15/38 , C12P21/02 , C07K14/03 , C12N5/10
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N2710/14143 , C12N2710/16622 , Y10S930/224
摘要： The present invention provides variant HSV-1 glycoprotein D and HSV-2 glycoprotein D molecules capable of preventing infection of cells by herpes simplex virus types 1 and/or 2. Also provided are novel purified and isolated polynucleotides encoding the variant gD molecules. HSV gD-1 and gD-2 region IV variants or fragments thereof are specifically contemplated by the invention. The presently preferred variant molecule gD-1(.DELTA.290-299t) is the product of recombinant expression in Sf9 cells of a fusion protein including the signal peptide of honeybee melittin and Patton strain HSV-1 gD wherein (1) the Patton strain amino acid residues 290 through 299 of the mature gD-1 protein have been replaced with the amino acid residues arginine, lysine, isoleucine and phenylalanine, and (2) Patton strain amino acid residues 308 through 369 have been replaced with five histidine residues. When exposed in Sf9 cells, cleavage of the melittin signal peptide results in the presence of aspartate and proline residues at the amino terminus of the variant molecule. The amino acid sequence of gD-1(.DELTA.290-299t) is set out in SEQ ID NO: 2 and the preferred DNA sequence encoding gD-1(.DELTA.290-299t) is set out in SEQ ID NO: 1. Administration of gD variant molecules of the invention to mammalian subjects, especially humans, for the purpose of preventing HSV infection and/or ameliorating pathological sequelae of HSV infection is specifically contemplated.
摘要翻译： PCT No.PCT / US96 / 11344 Sec。 371日期1997年5月7日 102（e）日期1997年5月7日PCT PCT 1996年7月3日PCT公布。公开号WO97 / 03199 日期1997年1月30日本发明提供能够预防1型和/或2型单纯疱疹病毒感染细胞的变体HSV-1糖蛋白D和HSV-2糖蛋白D分子。还提供了编码该变体的新型纯化和分离的多核苷酸 gD分子。 HSV gD-1和gD-2区IV变体或其片段是本发明具体考虑的。目前优选的变体分子gD-1（DELTA 290-299t）是在融合蛋白的Sf9细胞中重组表达的产物，包括蜜蜂蜂毒素和巴顿菌株HSV-1 gD的信号肽，其中（1）Patton菌株氨基酸成熟gD-1蛋白的残基290至299已被氨基酸残基精氨酸，赖氨酸，异亮氨酸和苯丙氨酸替代，（2）Patton菌株氨基酸残基308至369被五个组氨酸残基取代。当在Sf9细胞中暴露时，蜂毒肽信号肽的切割导致变体分子的氨基末端存在天冬氨酸和脯氨酸残基。 gD-1（DELTA 290-299t）的氨基酸序列示于SEQ ID NO：2中，编码gD-1（DELTA 290-299t）的优选DNA序列列于SEQ ID NO：1中。具体考虑本发明的gD变体分子对于哺乳动物受试者，特别是人来说是为了预防HSV感染和/或改善HSV感染的病理后遗症的目的。

7. 发明授权

US4751177A Methods and kits for performing nucleic acid hybridization assays 失效
标题翻译：用于进行核酸杂交测定的方法和试剂盒
公开(公告)号：US4751177A
公开(公告)日：1988-06-14
申请号：US744509
申请日：1985-06-13
申请人： Yitzhak Stabinsky
发明人： Yitzhak Stabinsky
IPC分类号： C12Q1/68 , C12Q1/70
CPC分类号： C12Q1/705 , C12Q1/6813 , Y10S435/81 , Y10S435/814 , Y10S436/808 , Y10S436/824 , Y10S930/224
摘要： A method for the isolation and quantitative detection of a selected single-stranded target polynucleotide from solution. The target polynucleotide is hybridized in solution to a single-stranded mediator polynucleotide, a probe polynucleotide, and an immobilized polynucleotide sequence. The sequence of the mediator polynucleotide comprises a first sequence complementary to a first portion of the target polynucleotide sequence and a second nucleotide sequence complementary to a portion of a single-stranded immobilized polynucleotide sequence. The probe polynucleotide, which carries a detectable label, is complementary to a second portion of the necleotide sequence of the target. The immobilized polynucleotide is immobilized by attachment to a solid support, and, through hybridization to the mediator polynucleotide, functions to immobilize the entire immobilized polynucleotide/target polynucleotide/probe polynucleotide "sandwich".
摘要翻译：从溶液中分离和定量检测所选择的单链靶多核苷酸的方法。靶多核苷酸在溶液中与单链介体多核苷酸，探针多核苷酸和固定的多核苷酸序列杂交。介体多核苷酸的序列包含与靶多核苷酸序列的第一部分互补的第一序列和与单链固定的多核苷酸序列的一部分互补的第二核苷酸序列。载有可检测标记的探针多核苷酸与目标核苷酸序列的第二部分互补。固定化的多核苷酸通过连接固体支持物被固定化，并且通过与介体多核苷酸杂交，起作用来固定整个固定的多核苷酸/靶多核苷酸/探针多核苷酸“三明治”。

8. 发明授权

US4707358A Vaccine against Epstein-Barr Virus 失效
标题翻译：针对爱泼斯坦 - 巴尔病毒的疫苗
公开(公告)号：US4707358A
公开(公告)日：1987-11-17
申请号：US633558
申请日：1984-07-23
申请人： Elliott Kieff , Jerome Tanner , Mary Hummel , Christopher Beisel
发明人： Elliott Kieff , Jerome Tanner , Mary Hummel , Christopher Beisel
IPC分类号： A61K39/00 , C07K14/05 , A61K39/245 , A61K37/02 , C07K13/00
CPC分类号： C07K14/005 , A61K39/00 , C12N2710/16222 , Y10S930/224
摘要： The nucleotide sequence of Epstein-Barr Virus (EBV) DNA which codes for outer surface viral proteins has been determined. Fragments of the DNA have been isolated and cloned into a vector which, when placed in a host organism, express proteins which when used to immunize rabbits generate antibody which reacts with the surface proteins of virus infected cells. These proteins are useful for preparation of a vaccine for EBV.
摘要翻译：已经确定了编码外表面病毒蛋白的爱泼斯坦 - 巴尔病毒（EBV）DNA的核苷酸序列。已经分离出DNA的片段并将其克隆到载体中，当被放置在宿主生物中时，其表达蛋白质，当用于免疫兔子时产生与病毒感染细胞的表面蛋白质反应的抗体。这些蛋白质可用于制备EBV疫苗。

9. 发明授权

US4761470A Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody 失效
标题翻译：能够引发单纯疱疹病毒中和抗体的免疫原性合成肽
公开(公告)号：US4761470A
公开(公告)日：1988-08-02
申请号：US036651
申请日：1987-04-10
申请人： Emilio A. Emini , Vivian M. Larson , Joshua S. Boger
发明人： Emilio A. Emini , Vivian M. Larson , Joshua S. Boger
IPC分类号： C07K14/035 , C07K16/08 , C07K7/08
CPC分类号： C07K16/087 , C07K14/005 , C12N2710/16622 , Y10S930/224
摘要： A synthetic peptide, containing the predicted amino acid residues 64 to 77 of the herpes simplex virus type 1 (HSV1) gB structural glycoprotein open reading frame, a synthetic subunit immunogen that stimulates an immune response against HSV1 and which, when prepared, and chemically-conjugated to a protein carrier molecule, and inoculated into test animals, gives rise to a specific anti-peptide IgG response, such that these anti-peptide antibodies react with a purified HSV-specific structural glycoprotein preparation and are capable of neutralizing the infectivity of HSV1.
摘要翻译：含有单纯疱疹病毒1型（HSV1）gB结构糖蛋白开放阅读框的预测氨基酸残基64至77的合成肽，刺激针对HSV1的免疫应答的合成亚单位免疫原，与蛋白质载体分子缀合并接种到测试动物中产生特异性抗肽IgG应答，使得这些抗肽抗体与纯化的HSV特异性结构糖蛋白制剂反应并能够中和HSV1的感染性。

10. 发明授权

US4745182A Herpes virus specific immunological materials and methods 失效
标题翻译：疱疹病毒特异性免疫学材料和方法
公开(公告)号：US4745182A
公开(公告)日：1988-05-17
申请号：US696582
申请日：1985-01-31
申请人： Gary H. Cohen , Roselyn J. Eisenberg
发明人： Gary H. Cohen , Roselyn J. Eisenberg
IPC分类号： A61K20060101 , A61K39/245 , A61K39/395 , A61K39/42 , A61P31/12 , B43L1/04 , C07K20060101 , C07K1/16 , C07K1/22 , C07K14/00 , C07K14/005 , C07K14/03 , C07K14/035 , C07K14/195 , C07K16/00 , C07K16/08 , C07K19/00 , C12N20060101 , C12N5/00 , C12N5/10 , C12N5/12 , C12N15/00 , C12N15/02 , C12P21/00 , C12P21/08 , C12R1/91 , G01N33/53 , G01N33/569 , G01N33/571 , G01N33/577 , C07K15/00
CPC分类号： C07K16/087 , C07K14/005 , C12N2710/16622 , Y10S435/948 , Y10S530/808 , Y10S530/809 , Y10S530/81 , Y10S530/811 , Y10S930/224
摘要： Disclosed are antibody substances displaying unique, multi-specific immunoreactivities with respect to glycoprotein D of Herpes Simplex Virus types 1 and 2 (HSV gD-1 and gD-2) and structurally related compounds. Illustratively, an IgG Type 2 monoclonal antibody material produced by mouse-mouse hybridoma cell line A.T.C.C. No. HB8606 is capable of in vitro neutralization of HSV-1 and HSV-2 infectivity and of specific immunological reactivity and reversible immunobinding with natrually-occuring and recombinant gD-1 and gD-2 in both native and denatured conformations as well as with proteinaceous materials (produced, e.g., by proteolytic digestion of naturally-occurring materials, by recombinant methods, or by polymerization of amino acids) which comprise a primary structural conformation substantially duplicating part or all of that which is predicted to be extant at residues 266 through 287 of gD-1 and gD-2 [i.e., PELA(or V)PEDPEDSALLEDPV(or A)GTVA(or S)]. Disclosed also are novel procedures for detection, quantification and isolation by affinity purification of gD-1, gD-2 and structurally related compounds.
摘要翻译：公开了针对1型和2型单纯疱疹病毒（HSV gD-1和gD-2）和结构相关化合物的糖蛋白D显示独特，多特异性免疫反应性的抗体物质。说明性地，由小鼠 - 小鼠杂交瘤细胞系A.T.C.C.生产的IgG 2型单克隆抗体材料。 HB8606能够体外中和HSV-1和HSV-2感染性以及特异性免疫反应性和可天然存在的重组gD-1和gD-2在天然和变性构象以及蛋白质样品中的可逆免疫结合材料（通过天然存在的材料的蛋白水解消化，通过重组方法或通过氨基酸的聚合产生），其包含主要结构构象，其基本上复制了预计在残基266至287存在的部分或全部的gD-1和gD-2 [即，PELA（或V）PEDPEDSALLEDPV（或A）GTVA（或S）]。还公开了通过亲和纯化gD-1，gD-2和结构相关化合物进行检测，定量和分离的新方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式